作者:Paul Renton、Brenda Green、Shawn Maddaford、Suman Rakhit、John S. Andrews
DOI:10.1021/ml200268w
日期:2012.3.8
A novel series of benzimidazole designed multiple ligands (DMLs) with activity at the neuronal nitric oxide synthase (nNOS) enzyme and the mu-opioid receptor was developed. Targeting of the structurally dissimilar heme-containing enzyme and the mu-opioid GPCR was predicated on the modulatory role of nitric oxide on mu-opioid receptor function. Structure activity relationship studies yielded lead compound 24 with excellent nNOS inhibitory activity (IC50 = 0.44 mu M), selectivity over both endothelial nitric oxide synthase (10-fold) and inducible nitric oxide synthase (125-fold), and potent mu-opioid binding affinity, K-i = 5.4 nM. The functional activity as measured in the cyclic adenosine monosphospate secondary messenger assay resulted in full agonist activity (EC50 = 0.34 mu M). This work represents a novel approach in the development of new analgesics for the treatment of pain.
SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY
申请人:Neuraxon Inc.
公开号:EP1888568A2
公开(公告)日:2008-02-20
EP1888568A4
申请人:——
公开号:EP1888568A4
公开(公告)日:2009-08-12
US7919510B2
申请人:——
公开号:US7919510B2
公开(公告)日:2011-04-05
[EN] SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY<br/>[FR] COMPOSES DE BENZIMIDAZOLE SUBSTITUES A ACTION A LA FOIS INHIBITRICE DE NOS ET AGONISTE OPIOIDE MU
申请人:NEURAXON INC
公开号:WO2007017764A2
公开(公告)日:2007-02-15
(EN) The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu- opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain.(FR) La présente invention porte sur des composés de benzimidazole présentant à la fois une action inhibitrice de la synthase d'oxyde nitrique (NOS) et une action agoniste au niveau du récepteur opioïde mu, sur des compositions pharmaceutiques et diagnostiques les contenant et sur leur utilisation médicale, en particulier comme composés pour le traitement ou la prévention de la douleur chronique, de la douleur aiguë, de la migraine et de la douleur neuropathique.